US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Invesco S&P SmallCap Health Care ETF

54.70

-0.1760-0.32%

Volume:2K

Turnover:82.76K

Market Cap:184.35M

PE:- -

High:54.70

Open:54.70

Low:54.70

Close:54.88

52wk High:56.45

52wk Low:39.08

Shares:3.37M

Float Shares:3.37M

Volume Ratio:0.22

T/O Rate:0.04%

Dividend:0.00

Dividend Rate:0.01%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Regeneron’s Pasatru granted FDA approval for FOP

Glenmark Wins U.S. FDA Nod for Generic Flonase Nasal Spray

Femasys announces FDA approval of FemBloc modular premarket approval application

Corcept Chief Business Officer Gary Charles Robb Sells 10,000 Shares for $1.16 Million

Amylyx Phase 3 data support FDA approval, says Citi

Corcept Therapeutics Incorporated : Truist Securities Assumes Coverage with Buy Rating; Target Price $164 vs $50

THOMSON REUTERS

Alkermes SVP, Chief Commercial Officer Christian Todd Nichols Sells 7,576 Shares for $374,301.99

Health Insurers are Dumping Medicare Advantage Plans. Here's How Many Seniors Could be Affected.

Krystal Biotech Director Dino A. Rossi Disposes of USD 8.17 Million in Common Shares

Krystal Biotech Seen Positioned for Further Gains on Vyjuvek, Pipeline Readouts, RBC Says

MT Newswires Live

Krystal Biotech, Inc. : RBC Initiates Coverage with Outperform Rating; Target Price $400

THOMSON REUTERS

BrightSpring Health Svcs Price Target Maintained with a $90.00/Share by BTIG

BofA Securities Boosts Targets on Chinese CXO Players as Strong Biotech Funding Fuels R&D

Bank of America Securities Raises Targets for Chinese CXO Firms on Strong Biotech Funding

Outlook Therapeutics Ends ATM Prospectus Amid Ongoing Risks

Corcept Chief Development Officer William Guyer Disposes of Common Shares Worth $1.85 Million

Alkermes Cuts Interest Spreads on $1.52 Billion Term Loan Facilities Via Credit Agreement Amendment

Alkermes - Enters Amendment No. 1 to Credit Agreement on August 12, 2026 - SEC Filing

THOMSON REUTERS

Alkermes - Amendment Reduces Interest Rate Spread Under Tla by 0.75% and Tlb by 0.50% - SEC Filing

THOMSON REUTERS

Health Insurers are Dumping Medicare Advantage Plans. Here's How Many Seniors Could be Affected.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/PSCH/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PSCH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSCH\",,,,,undefined,":{"symbol":"PSCH","market":"US","secType":"STK","nameCN":"Invesco S&P SmallCap Health Care ETF","latestPrice":54.704,"timestamp":1788451233585,"preClose":54.88,"halted":0,"volume":1511,"delay":0,"changeRate":-0.00320699708454814,"floatShares":3370000,"shares":3370000,"eps":0,"marketStatus":"Trading","change":-0.176,"latestTime":"09-03 12:01:02 EDT","open":54.7009,"high":54.704,"low":54.7009,"amount":82757.932366,"amplitude":0.000056,"askPrice":54.97,"askSize":500,"bidPrice":54.89,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788465600000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":54.88,"sharesOutstanding":3220000,"nav":54.508,"aum":183691960,"dividendRate":0.000055,"bidAskSpread":0.001979,"postHourTrading":{"tag":"盘后","latestPrice":54.88,"preClose":54.88,"latestTime":"16:15 EDT","volume":10,"amount":548.8,"timestamp":1788380100261,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.219754,"impliedVol":0.1092,"impliedVolPercentile":0.6825},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSCH\",,,,,undefined,":{"symbol":"PSCH","floatShares":3370000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.219754,"shares":3370000,"dividePrice":0.003,"high":54.704,"amplitude":0.000056,"preClose":54.88,"low":54.7009,"week52Low":39.08,"pbRate":"--","week52High":56.454,"institutionHeld":0,"latestPrice":54.704,"committee":-0.428571,"eps":0,"divideRate":0.000055,"volume":1511,"delay":0,"ttmEps":0,"open":54.7009,"prevYearClose":44.0553,"prevWeekClose":54.65,"prevMonthClose":54.61,"prevQuarterClose":52.3666,"fiveDayClose":55.44,"twentyDayClose":54.01,"sixtyDayClose":47.3417},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PSCH\",params:#limit:5,,,undefined,":[{"date":"2026-03-23","symbol":"PSCH","amount":0.00033,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"Invesco S&P SmallCap Health Care ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-09-22","symbol":"PSCH","amount":0.00259,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"Invesco S&P SmallCap Health Care ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"},{"date":"2025-06-23","symbol":"PSCH","amount":0.00199,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"Invesco S&P SmallCap Health Care ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"},{"date":"2025-03-24","symbol":"PSCH","amount":0.01419,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-24","defaultRemindTime":1742823000000,"name":"Invesco S&P SmallCap Health Care ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-28","payableDate":"2025-03-24","currency":"USD","dateTimestamp":1742788800000,"payDate":"2025-03-28"},{"date":"2024-12-23","symbol":"PSCH","amount":0.01801,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"Invesco S&P SmallCap Health Care ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-27","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PSCH\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-16","recordDate":"2016-12-20","paymentDate":"2016-12-30","value":0.01949,"currency":"USD"},{"executeDate":"2018-09-24","recordDate":"2018-09-25","paymentDate":"2018-09-28","value":0.00522,"currency":"USD"},{"executeDate":"2022-03-31","recordDate":null,"paymentDate":"2022-03-31","value":3,"currency":"USD"},{"executeDate":"2023-12-18","recordDate":"2023-12-19","paymentDate":"2023-12-22","value":0.00448,"currency":"USD"},{"executeDate":"2024-03-18","recordDate":"2024-03-19","paymentDate":"2024-03-22","value":0.03613,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PSCH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PSCH\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660287604","title":"Regeneron’s Pasatru granted FDA approval for FOP","url":"https://stock-news.laohu8.com/highlight/detail?id=2660287604","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660287604?lang=en_us&edition=fundamental","pubTime":"2026-08-20 21:20","pubTimestamp":1787232025,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration has approved Pasatru to reduce new heterotopic ossification and reduce clinician-assessed disease flare-ups i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regenerons-pasatru-granted-fda-approval-for-fop-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regenerons-pasatru-granted-fda-approval-for-fop-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLVX","IBB","IDNA","LABU","BBP","BK4585","FRTY","TBXU","PINK","IEIH","MEDI","LFSC","BK4588","GNMX","PSCH","MRNY","TECB","NVIB","GDOC","IYH","MRNX","BMED","RSPH","SYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660028408","title":"Glenmark Wins U.S. FDA Nod for Generic Flonase Nasal Spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2660028408","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660028408?lang=en_us&edition=fundamental","pubTime":"2026-08-20 12:43","pubTimestamp":1787200984,"startTime":"0","endTime":"0","summary":"Glenmark Pharmaceuticals Limited ( ($IN:GLENMARK) ) just unveiled an announcement. Glenmark Pharmaceuticals has secured U.S. FDA approval for its F...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/glenmark-wins-u-s-fda-nod-for-generic-flonase-nasal-spray?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/glenmark-wins-u-s-fda-nod-for-generic-flonase-nasal-spray?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","BMED","MEDI","MRNY","TBXU","GNMX","IEIH","BK4585","TECB","IBB","MRNX","PSCH","GDOC","SYNB","BBP","IYH","XLVX","LFSC","PINK","RSPH","LABU","BK4588","FRTY","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660252964","title":"Femasys announces FDA approval of FemBloc modular premarket approval application","url":"https://stock-news.laohu8.com/highlight/detail?id=2660252964","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660252964?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:16","pubTimestamp":1787145413,"startTime":"0","endTime":"0","summary":"Femasys (FEMY) announced that the FDA has approved the company’s modular premarket approval application pathway for FemBloc, its investigational no...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/femasys-announces-fda-approval-of-fembloc-modular-premarket-approval-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/femasys-announces-fda-approval-of-fembloc-modular-premarket-approval-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNMX","RSPH","MRNX","BK4539","BK4584","MEDI","LABU","FRTY","FEMY","TBXU","GDOC","NVIB","SYNB","LFSC","BK4082","BK4588","PSCH","BBP","MRNY","IEIH","XLVX","BK4585","TECB","IYH","IDNA","IBB","PINK","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660371492","title":"Corcept Chief Business Officer Gary Charles Robb Sells 10,000 Shares for $1.16 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2660371492","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660371492?lang=en_us&edition=fundamental","pubTime":"2026-08-19 04:31","pubTimestamp":1787085063,"startTime":"0","endTime":"0","summary":"Corcept Chief Business Officer Gary Charles Robb sells 10,000 shares for $1.16 millionCorcept Therapeutics Chief Business Officer Gary Charles Robb sold 10,000 common shares on Aug. 17.Sale priced at ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDLc47Ccv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Chief Business Officer Gary Charles Robb Sells 10,000 Shares for $1.16 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","FBT","LU1559883803.SGD","CORT","PSCH","BK4007","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660595493","title":"Amylyx Phase 3 data support FDA approval, says Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2660595493","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660595493?lang=en_us&edition=fundamental","pubTime":"2026-08-18 22:05","pubTimestamp":1787061936,"startTime":"0","endTime":"0","summary":"Citi says Amylyx’s (AMLX) avexitide showed a “highly differentiated” profile in the Phase 3 LUCIDITY study, a 78 participant, placebo-controlled tr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amylyx-phase-3-data-support-fda-approval-says-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amylyx-phase-3-data-support-fda-approval-says-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","GNMX","LABU","GDOC","IEIH","IYH","PINK","TECB","FRTY","IDNA","LFSC","RSPH","NVIB","MEDI","XLVX","BMED","BK4007","BK4585","TBXU","BBP","PSCH","IBB","AMLX","SYNB","MRNY","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660619704","title":"Corcept Therapeutics Incorporated : Truist Securities Assumes Coverage with Buy Rating; Target Price $164 vs $50","url":"https://stock-news.laohu8.com/highlight/detail?id=2660619704","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660619704?lang=en_us&edition=fundamental","pubTime":"2026-08-18 19:04","pubTimestamp":1787051049,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nFWN44F0P6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CORT","LU0566484027.USD","FBT","BK4532","LU1559883803.SGD","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660430568","title":"Alkermes SVP, Chief Commercial Officer Christian Todd Nichols Sells 7,576 Shares for $374,301.99","url":"https://stock-news.laohu8.com/highlight/detail?id=2660430568","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660430568?lang=en_us&edition=fundamental","pubTime":"2026-08-18 06:54","pubTimestamp":1787007262,"startTime":"0","endTime":"0","summary":"Alkermes SVP, Chief Commercial Officer Christian Todd Nichols sells 7,576 shares for $374,301.99Alkermes SVP, Chief Commercial Officer Christian Todd Nichols sold 7,576 ordinary shares on Aug. 17, 202","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDLbv4Lk0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alkermes SVP, Chief Commercial Officer Christian Todd Nichols Sells 7,576 Shares for $374,301.99","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","FBT","PSIL","MEDX","ALKS","PSCH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659173096","title":"Health Insurers are Dumping Medicare Advantage Plans. Here's How Many Seniors Could be Affected.","url":"https://stock-news.laohu8.com/highlight/detail?id=2659173096","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659173096?lang=en_us&edition=fundamental","pubTime":"2026-08-16 00:16","pubTimestamp":1786810560,"startTime":"0","endTime":"0","summary":"Coverage changes could leave rural markets with fewer choicesAbout 10% of the Medicare Advantage market was forced to find new plans in 2026. Coverage plans for 2027 will be finalized by Oct. 1.Older ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4154","BK4588","SG9999014039.USD","LU0170899867.USD","UNHU","LU0390134368.USD","SG9999014021.USD","MOH","IEHS","LNGR","BK4585","SG9999014005.SGD","BK4566","LU0256863811.USD","LU0417517546.SGD","LU0348723411.USD","LU1093756325.SGD","LU0211331839.USD","LU0070302665.USD","HUM","LU1093756168.USD","FXH","PSCH","XLVX","BK4533","IYH","IHF","SG9999014013.SGD","LU1983260115.SGD","XHS","LU0208291251.USD","BK4532","LU0266013472.USD","LU0238689110.USD","LU0320765489.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659124086","title":"Krystal Biotech Director Dino A. Rossi Disposes of USD 8.17 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2659124086","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659124086?lang=en_us&edition=fundamental","pubTime":"2026-08-15 06:23","pubTimestamp":1786746202,"startTime":"0","endTime":"0","summary":"Krystal Biotech Director Dino A. Rossi disposes of USD 8.17 million in common sharesDirector Dino A. Rossi cut his Krystal Biotech stake to 50,000 shares on Aug. 14, 2026.Disposed of 25,000 common sha","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL6DCXXB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Krystal Biotech Director Dino A. Rossi Disposes of USD 8.17 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS","PSCH","BK4139","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659140246","title":"Krystal Biotech Seen Positioned for Further Gains on Vyjuvek, Pipeline Readouts, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2659140246","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659140246?lang=en_us&edition=fundamental","pubTime":"2026-08-14 23:11","pubTimestamp":1786720282,"startTime":"0","endTime":"0","summary":"Krystal Biotech  has further room for gains driven by Vyjuvek, its treatment for the rare blistering condition dystrophic epidermolysis bullosa, alongside international launches and growth across its gene therapy pipeline, RBC Capital said Friday in a report.Krystal's neurotrophic keratitis program could be its next major catalyst, with pivotal data expected in early 2027, RBC said. Shares may rise 30% if results match the current standard of care, while a weak outcome might prompt a 15% decline, the report said.RBC forecasts peak NK sales of $2.1 billion in 2030, citing the established market and potential for the therapy to become a best-in-class treatment, though the outlook remains \"cautiously optimistic\" given limited clinical data.Vyjuvek holds more than 60% of the US market, while international launches are expected to drive the next phase of growth, the report said. RBC projects Vyjuvek peak sales of $1 billion by 2033 and pointed to H2 readouts in ocular DEB, cystic fibrosis a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XBI","BK4581","BK4588","BK4585","HELX","PSCH","BK4139","KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659428117","title":"Krystal Biotech, Inc. : RBC Initiates Coverage with Outperform Rating; Target Price $400","url":"https://stock-news.laohu8.com/highlight/detail?id=2659428117","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659428117?lang=en_us&edition=fundamental","pubTime":"2026-08-14 17:39","pubTimestamp":1786700394,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nFWN44B0NL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KRYS","HELX","BK4139","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659156635","title":"BrightSpring Health Svcs Price Target Maintained with a $90.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2659156635","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659156635?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:03","pubTimestamp":1786618980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BTSG/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","LU2468319806.SGD","LU2089984988.USD","PSCH","LU2324357040.USD","BTSG","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155684243","title":"BofA Securities Boosts Targets on Chinese CXO Players as Strong Biotech Funding Fuels R&D","url":"https://stock-news.laohu8.com/highlight/detail?id=1155684243","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155684243?lang=en_us&edition=fundamental","pubTime":"2026-08-13 12:50","pubTimestamp":1786596641,"startTime":"0","endTime":"0","summary":"BofA Securities has released a report indicating that the Chinese CXO sector is poised to benefit from robust biotech venture capital funding. The bank notes that strong financing in the first half...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBIX","PSIL","IE00BPRC5H50.USD","LU2242644610.SGD","BMED","APXH","LU1251922891.USD","LU1934453819.USD","LU1997245094.SGD","LU1969619763.USD","IBRN","161027","CXO","LU1303224171.USD","SMCO","IE00B5MMRT66.SGD","BBC","IE00B543WZ88.USD","LU0700851271.USD","LU0708995583.HKD","PSCH","SURI","LU2125910500.SGD","LU1997245177.USD","LU2488822045.USD","LU2045819591.USD","02359","MEDI","BK1583","BK1576","LU1046422090.SGD","LU2495084118.USD","IDNA","LU0320764599.SGD","LU0348767384.USD","LU1808992512.USD","BK1141","LU1770034418.SGD","FHLC","LU0348766576.USD","LFSC","LU2328871848.SGD","LU0611395673.USD","LU0456842615.SGD","BK0216","LU1719994722.HKD","603259","LU0052750758.USD","LU1997244956.HKD","LU1979443071.USD","WX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111112440","title":"Bank of America Securities Raises Targets for Chinese CXO Firms on Strong Biotech Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=1111112440","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111112440?lang=en_us&edition=fundamental","pubTime":"2026-08-13 10:35","pubTimestamp":1786588544,"startTime":"0","endTime":"0","summary":"A report from Bank of America Securities indicates that Chinese CRO/CDMO companies are poised to benefit from robust first-half funding in the global and Chinese biotech sectors, along with active...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","LU0359201612.USD","LU0417516738.SGD","LU1720050803.USD","LU0823426480.USD","LU1997245094.SGD","03759","LU0823426308.USD","LU0979878070.USD","LU1794554557.SGD","LU0708995583.HKD","BK1583","LU1303224171.USD","APXH","IBRN","LU0039217434.USD","LU2125910500.SGD","LU1979443071.USD","LU0516422952.EUR","LU0572944931.SGD","LU1242518931.SGD","BMED","LU1688375341.USD","LU0181495838.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU0327786744.USD","XBIX","LU0140636845.USD","LU0052750758.USD","LU1880383366.USD","LU0417516902.SGD","SMCO","CXO","LU0588546209.SGD","FHLC","SG9999002562.SGD","PSIL","IE00BPRC5H50.USD","LU1251922891.USD","BK1589","LU1046422090.SGD","BBC","02359","603259","LU0456846285.SGD","LU1242518857.USD","LU0700851271.USD","LU0456827905.SGD","LU0516422440.USD","BK0216","LU2039709279.SGD","LU1808992512.USD","LU0359202008.SGD","LU3063872942.SGD","MEDI","LU1934453819.USD","LU2495084118.USD","LU0348825331.USD","BK1576","LU2488822045.USD","LU0029874061.USD","BK1610","BK1141","SG9999002463.SGD","WX","LU1997244956.HKD","LU0128526141.USD","LU2045819591.USD","LU0307460666.USD","LU0456842615.SGD","LU0348735423.USD","SURI","LU0516423091.SGD","02269","LU0348767384.USD","IE00B0JY6N72.USD","LU1969619763.USD","LU2328871848.SGD","BK1521","LU1719994722.HKD","LU0819121731.USD","LU0043850808.USD","LU0051755006.USD","LU0320764599.SGD","LU0326950275.SGD","LU0348766576.USD","LU0516423174.USD","161027","LU0516422366.SGD","IDNA","LU0611395673.USD","LU1997245177.USD","PSCH","LU2242644610.SGD","LU1770034418.SGD","LU0856984785.SGD","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659926188","title":"Outlook Therapeutics Ends ATM Prospectus Amid Ongoing Risks","url":"https://stock-news.laohu8.com/highlight/detail?id=2659926188","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659926188?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:37","pubTimestamp":1786567029,"startTime":"0","endTime":"0","summary":"The latest update is out from Outlook Therapeutics ( ($OTLK) ). On July 24, 2026, Outlook Therapeutics announced U.S. FDA approval of LYTENAVA (bev...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/outlook-therapeutics-ends-atm-prospectus-amid-ongoing-risks?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/outlook-therapeutics-ends-atm-prospectus-amid-ongoing-risks?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRNY","TBXU","LABU","MEDI","BK4139","PSCH","IBB","IEIH","BBP","BK4585","LENZ","GNMX","IDNA","GDOC","BK4588","BMED","LFSC","BK4007","SYNB","IYH","PINK","TECB","XLVX","BK4539","RSPH","NVIB","FRTY","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659900794","title":"Corcept Chief Development Officer William Guyer Disposes of Common Shares Worth $1.85 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659900794","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659900794?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:27","pubTimestamp":1786566428,"startTime":"0","endTime":"0","summary":"Corcept Chief Development Officer William Guyer disposes of common shares worth $1.85 millionCorcept disclosed Chief Development Officer William Guyer exercised options for 16,300 shares at $ 21.65 on","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL2qSVvx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Chief Development Officer William Guyer Disposes of Common Shares Worth $1.85 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","FBT","LU1559883803.SGD","PSCH","CORT","BK4007","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658906555","title":"Alkermes Cuts Interest Spreads on $1.52 Billion Term Loan Facilities Via Credit Agreement Amendment","url":"https://stock-news.laohu8.com/highlight/detail?id=2658906555","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658906555?lang=en_us&edition=fundamental","pubTime":"2026-08-12 23:19","pubTimestamp":1786547988,"startTime":"0","endTime":"0","summary":"Alkermes cuts interest spreads on $1.52 billion term loan facilities via credit agreement amendmentAlkermes entered an amendment on Aug. 12, 2026 to its Feb. 12, 2026 credit agreement with JPMorgan Chase Bank.The deal covers senior secured term loan A of USD 745.31 million, due Feb. 12, 2031, and term loan B of USD 773.06 million, due Aug. 12, 2031.The amendment cuts the interest spread by 0.75% on the term loan A facility, 0.5% on the term loan B facility.Term loan A now prices at Term SOFR plus 1.75%-2.25%, or base rate plus 0.75%-1.25%, based on secured net leverage.Term loan B now prices at Term SOFR plus 2.25%, or base rate plus 1.25%.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alkermes plc published the original content used t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL3L5Jbs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BYXW3230.USD","JPMO","LU2357305700.SGD","TFNS","JPX","LU1363072403.SGD","LU0320765646.SGD","LU1551013425.SGD","LU2552382215.SGD","LU1496350502.SGD","FBT","LU1116320901.HKD","KBWB","LU1629891620.HKD","LU2505996681.GBP","MEDX","TRUF","LU2106854487.HKD","IXG","LU0211331839.USD","LU0320765489.SGD","LU0345770993.USD","LU0496365809.HKD","LU2237443622.USD","LU1162221912.USD","LU1720051017.SGD","LU0211326755.USD","LU1974910355.USD","LU0234572021.USD","LU2456880835.USD","LU2054465674.USD","FNCL","LU2023250843.SGD","LU0106261372.USD","PSIL","JPO","LU0208291251.USD","PSCH","LU2462157665.USD","XLF","UYG","VFH","IBRN","ALKS","FTXO","IE00BZ1G4Q59.USD","IYF","IYG","LU0265550946.USD","LU2552382132.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658908840","title":"Alkermes - Enters Amendment No. 1 to Credit Agreement on August 12, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2658908840","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658908840?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:27","pubTimestamp":1786541257,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4491BU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBT","BK4139","IBRN","PSIL","MEDX","ALKS","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658908808","title":"Alkermes - Amendment Reduces Interest Rate Spread Under Tla by 0.75% and Tlb by 0.50% - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2658908808","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658908808?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:27","pubTimestamp":1786541257,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4491BU:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBT","PSIL","MEDX","PSCH","IBRN","ALKS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658391758","title":"Health Insurers are Dumping Medicare Advantage Plans. Here's How Many Seniors Could be Affected.","url":"https://stock-news.laohu8.com/highlight/detail?id=2658391758","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658391758?lang=en_us&edition=fundamental","pubTime":"2026-08-12 02:02","pubTimestamp":1786471320,"startTime":"0","endTime":"0","summary":"Coverage changes could leave rural markets with fewer choicesAbout 10% of the Medicare Advantage market was forced to find new plans in 2026. Coverage plans for 2027 will be finalized by Oct. 1.Older ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","FXH","BK4154","SG9999014013.SGD","SG9999014039.USD","PSCH","XHS","MOH","LU0208291251.USD","LU0070302665.USD","BK4566","IEHS","LU0170899867.USD","LU0417517546.SGD","LU1093756168.USD","LU1983260115.SGD","BK4585","IHF","BK4532","LU0390134368.USD","LU0238689110.USD","BK4588","SG9999014021.USD","LU0211331839.USD","HUM","LU0266013472.USD","UNHU","SG9999014005.SGD","IYH","XLVX","LNGR","LU0348723411.USD","LU1093756325.SGD","LU0320765489.SGD","LU0256863811.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}